Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults

Jesse Nussbaum; Xin Cao; Radha A Railkar; Jeffrey R Sachs; Daniel S Spellman; Julie Luk; Christine A Shaw; Pedro J Cejas; Michael P Citron; Mohamed Al-Ibrahim; David Han; Sandra Pagnussat; S Aubrey Stoch; Eseng Lai; Andrew J Bett; Amy S Espeseth

doi:10.1016/j.vaccine.2023.05.062

Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults

Vaccine. 2023 Oct 20;41(44):6488-6501. doi: 10.1016/j.vaccine.2023.05.062. Epub 2023 Sep 29.

Authors

Affiliations

¹ Merck & Co., Inc., Rahway, NJ, USA. Electronic address: jesse.nussbaum@merck.com.
² Merck & Co., Inc., Rahway, NJ, USA.
³ Moderna Inc., Cambridge, MA, USA.
⁴ Pharmaron, Baltimore, MD, USA.
⁵ Parexel, Glendale, CA, USA.
⁶ QPS, Miami, FL, USA.

PMID: 37777449
DOI: 10.1016/j.vaccine.2023.05.062

Abstract

Human respiratory syncytial virus (RSV) causes a substantial proportion of respiratory tract infections worldwide. Although RSV reinfections occur throughout life, older adults, particularly those with underlying comorbidities, are at risk for severe complications from RSV. There is no RSV vaccine available to date, and treatment of RSV in adults is largely supportive. A correlate of protection for RSV has not yet been established, but antibodies targeting the pre-fusion conformation of the RSV F glycoprotein play an important role in RSV neutralization. We previously reported a Phase 1 study of an mRNA-based vaccine (V171) expressing a pre-fusion-stabilized RSV F protein (mDS-Cav1) in healthy adults. Here, we evaluated an mRNA-based vaccine (V172) expressing a further stabilized RSV pre-fusion F protein (mVRC1). mVRC1 is a single chain version of RSV F with interprotomer disulfides in addition to the stabilizing mutations present in the mDS-Cav1 antigen. The immunogenicity of the two mRNA-based vaccines encoding mVRC1 (V172) or a sequence-optimized version of mDS-Cav1 to improve transcriptional fidelity (V171.2) were compared in RSV-naïve and RSV-experienced African green monkeys (AGMs). V172 induced higher neutralizing antibody titers than V171.2 and demonstrated protection in the AGM challenge model. We conducted a Phase 1, randomized, placebo-controlled, clinical trial of 25 μg, 100 μg, 200 μg, or 300 μg of V172 in healthy older adults (60-79 years old; N = 112) and 100 μg, 200 μg, or 300 μg of V172 in healthy younger adults (18-49 years old; N = 48). The primary clinical objectives were to evaluate the safety and tolerability of V172, and the secondary objective was to evaluate RSV serum neutralization titers. The most commonly reported solicited adverse events were injection-site pain, injection-site swelling, headache, and tiredness. V172 was generally well tolerated in older and younger adults and increased serum neutralizing antibody titers, pre-fusion F-specific competing antibody titers, and RSV F-specific T-cell responses.

Keywords: Human respiratory syncytial virus; Immunogenicity; Phase 1 clinical trial; Preclinical animal model; Safety; mRNA vaccine.